Comparative Pharmacology
Head-to-head clinical analysis: BALZIVA 21 versus DEMULEN 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALZIVA 21 versus DEMULEN 1 35 21.
BALZIVA-21 vs DEMULEN 1/35-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BALZIVA-21 is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) signaling by binding to VEGF-A and preventing its interaction with VEGF receptors (VEGFR-1 and VEGFR-2), thereby reducing angiogenesis and tumor vascularization.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and ethynodiol diacetate (progestin). Inhibits gonadotropin secretion (FSH, LH) via negative feedback on hypothalamic-pituitary axis, suppressing ovulation. Additionally, thickens cervical mucus and alters endometrial receptivity.
BALZIVA-21 is administered 150 mg orally twice daily.
One tablet orally once daily for 21 days, followed by 7 days off. Each tablet contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol.
None Documented
None Documented
Terminal half-life: 18 hours (range 12-24 hr); prolonged in renal impairment
Ethinyl estradiol: 13±3 hours (terminal); norethindrone: 8±3 hours. Steady-state achieved after ~5 days.
Renal: 70% unchanged; biliary/fecal: 20%; 10% metabolized
Renal (primarily as glucuronide and sulfate conjugates): ~60%; fecal: ~40%
Category C
Category C
Oral Contraceptive
Oral Contraceptive